Latest News & Updates

Breaking News

38 minutes ago
Pharma Now Editorial Team

Lupin Gains Tentative FDA Approval for Revefenacin Inhalation Solution in COPD

EMA Publishes First Quarterly Report Tracking EU Clinical Trial Targets Against 2030 Benchmarks

Pharma Now Editorial Team

Roivant Secures $2.25B LNP Patent Settlement with Moderna via Genevant and Arbutus

Pharma Now Editorial Team

Jupiter Neurosciences Secures $100M Term Sheet with PharmAla for U.S. Rights to NCE-Designated MDMA Compound ALA-002

Pharma Now Editorial Team

ACG Flags Dosage Form Design as a Primary Driver of Medication Non-Adherence in Elderly Patients

Pharma Now Editorial Team

Other trending news you may like to read

Lupin Gains Tentative FDA Approval for Revefenacin Inhalation Solution in COPD

Lupin receives tentative FDA approval for generic Revefenacin inhalation solution, meeting ANDA requirements for COPD maintenance treatment.

Pharma Now Editorial Team

EMA Publishes First Quarterly Report Tracking EU Clinical Trial Targets Against 2030 Benchmarks

EMA's first 2030 clinical trial progress report shows 40.5% of trials recruiting within 200 days, against a 66% target.

Pharma Now Editorial Team

Roivant Secures $2.25B LNP Patent Settlement with Moderna via Genevant and Arbutus

Roivant's $2.25B LNP patent settlement with Moderna highlights IP risk for manufacturers using lipid nanoparticle delivery platforms.

Pharma Now Editorial Team

Jupiter Neurosciences Secures $100M Term Sheet with PharmAla for U.S. Rights to NCE-Designated MDMA Compound ALA-002

Jupiter Neurosciences signs a $100M term sheet for U.S. rights to PharmAla's NCE-designated MDMA compound ALA-002, amid shifting DEA and FDA psychedelic policy.

Pharma Now Editorial Team